Enriching the lives of pets and their owners with breakthrough therapeutics

Therapeutic Areas

Cardiology

Targeted treatments for complex, chronic heart diseases in cats and dogs

Pain Management

Next generation veterinary pain management for daily use

Gastroenterology

The world’s first veterinary registered PPI for canine gastric ulceration

Wellness Testing

Diagnostics for Gastric markers that indicate health and wellness

Age related decline

Tackling some of the most debilitating and chronic diseases of aging in companion animals

Areas of Focus
Cardiology

Targeted treatments for complex, chronic heart diseases in cats and dogs

Product Launch Expected:

US product launch Q4 2023
EU launch Q1 2024

Pain Management

Next generation veterinary pain management for daily use

Product Launch Expected:

US product launch Q1 2024;
Q2 2024

Gastroenterology

The world’s first veterinary registered PPI for canine gastric ulceration

Product Launch Expected:

US product launch Q1 2023
EU launch Q3 2023

Wellness Testing

Diagnostics for Gastric markers that indicate health and wellness

Product Launch Expected:

US/EU product launch Q2 2023

Age related decline

Tackling some of the most debilitating and chronic diseases of aging in companion animals

In research and development

Our research and development model is simple but effective.

WE IDENTIFY

We identify diseases in companion animals where there are no approved treatments.

WE FORMULATE

We formulate novel solutions with species specific doses and presentations.

WE TRIAL

Our research team are bridging the gap between bench and bedside by conducting clinical trials that benefit client-owned dogs and cats.

WE COLLATE

The data collected is then used as clinical data for veterinary patients

WE PROVE

We prove the safety and efficacy of our products to FDA and EMA requirements.

Our research and development model is simple but effective.

WE IDENTIFY

We identify diseases in companion animals where there are no approved treatments.

WE FORMULATE

We formulate novel solutions with species specific doses and presentations.

WE TRIAL

Our translational research team are bridging the gap between bench and bedside by conducting clinical trials that benefit client-owned dogs and cats.

WE COLLATE

The data collected is then used both as clinical data for veterinary patients and preclinical data for human patients.

WE PROVE

We prove the safety and efficacy of our products to FDA and EMA requirements.

WE TRANSLATE

We harness our extensive animal research to identify synergies in human medicine.

Insights

Keep up to date with our latest advancements and news as we continue to develop and commercialise medicines and diagnostics for use in companion animals.

Felycin™ Feline HCM product prevented progression of hypertrophy - Results of the RapaCat Study published in JAVMA

TriviumVet are proud to announce the publication of the results of the RapaCat Study in the Journal of the American Veterinary Medical Association. This study used our proprietary veterinary mTOR inhibitor Felycin™ to target early Hypertrophic Cardiomyopathy (HCM) and was tested in stage B1 and B2 client-owned cats with the disease. Felycin™ prevented progression of hypertrophy.

July 28, 2023
S&P Global Animal Health Interview TriviumVet CEO Louise Grubb on upcoming product authorizations

Catch up on all the latest news from TriviumVet and their range of candidates targeting cardiology, pain, gastroenterology, age-related diseases and general wellness.

July 28, 2023
Congratulations to NC State’s Olby as she Wins 2023 AVMA Career Achievement in Canine Research Award

At TriviumVet we are delighted to work with some of the veterinary industry's most passionate, knowledgeable and renowned thought leaders. We started working with Dr. Olby on the CHASE Questionnaire study to assess a novel pain management product in dogs. This award is an incredible recognition of her research career and achievements. Well done Dr. Olby!

July 18, 2023

“Until one has loved an animal, a part of one’s soul remains unawakened”

Anatole France